SCHEMBL26022261

SCHEMBL26022261

CCC(=O)C(Oc1ccccc1Cl)C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
MAPT P10636 1/20 0.45
HPGD P15428 5/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 3/20 0.42
TSHR P16473 1/20 0.42
PKM P14618 1/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 1/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SLC6A9 P48067 1/20 0.38
CXCL8 P10145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21618150 0.89 ALDH1A1 (0.50) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL31560857 0.80 ALDH1A1 (0.49) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL7323206 0.80 ALDH1A1 (0.48) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL28729952 0.78 KMT2A (0.56) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL15262747 0.76 PPARG (0.43) ALDH1A1LMNATSHRSMN1; SMN2NOS3
SCHEMBL17156294 0.76 ALDH1A1 (0.47) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL27561768 0.75 PPARA (0.43) HPGDLMNATSHR
SCHEMBL14278560 0.74 ALDH1A1 (0.44) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL4015947 0.74 CASP1 (0.47) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL9423833 0.73 ALDH1A1 (0.47) ALDH1A1MAPTHPGDKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820573-B1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2023-08-09 EP disclosed